APOC3 and atherosclerosis: Epidemiological studies and observational research have shown that increased levels of APOC3 lead to increased TG levels and a high risk of ASCVD, while LOF mutations in APOC3 are linked to decreased plasma TG levels and reduced cardiovascular disease risk among high-risk individuals [62,63].